Verifying…
Home / Drug A–Z / Taxenov Injection 20 mg/mL

Taxenov Injection 20 mg/mL

NAFDAC Reg. No. A4-101586 · Drug

Registered with NAFDAC. Registration activeAs of 28 October 2026 · synced automatically from official sources.
Product
Taxenov Injection 20 mg/mL
NAFDAC number
A4-101586
Active ingredient
Docetaxel (Docetaxel Trihydrate)
Strength
80 mg/4 mL
Form
Concentrate for solution for infusion
Pack size
4 mL x 1's (in vial)
Manufacturer
Not listed
Applicant (holder)
C.G. Biostadt Company Limited
Approved
29 Oct 2025
Status
Active View on NAFDAC ↗
Registration valid to
28 Oct 2030
WHO alerts
None found
Community reports
None
Times checked
0

What we found

  • Taxenov Injection 20 mg/mL is on the NAFDAC register with an active registration (A4-101586). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

What Taxenov Injection 20 mg/mL is used for

From the official U.S. FDA label for docetaxel (docetaxel trihydrate), the active ingredient registered with NAFDAC.

Boxed warning: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION Treatment-related mortality associated with docetaxel is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive docetaxel as a single agent at a dose of 100 mg/m 2 [see Warnings and Precautions ( 5.1 )] . …
What it is used for

1. INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untrea …

Possible side effects

6. ADVERSE REACTIONS The most serious adverse reactions from docetaxel are: • Toxic Deaths [see Boxed Warning, Warnings and Precautions ( 5.1 )] • Hepatic Impairment [see Boxed Warning, Warnings and Precautions ( 5.2 )] • Hematologic Effects [see Boxed Warning, Warnings and Precautions ( 5.3 )] • Enterocolitis and Neutropenic Colitis [see Warnings and Precautions ( 5.4 )] • Hypersensitivity Reactions [see Boxed Warning, Warnings and Precautions ( 5.5 )] • Fluid Retention [see Boxed Warning, Warnings and Precautions ( 5.6 )] • Second Primary Malignancies [see Warnings and Precautions ( 5.7 )] • Cutaneous Reactions [see Warnings and Precautions ( 5.8 )] • Neurologic Reactions [ see Warnings an …

Do not use if

4. CONTRAINDICATIONS Docetaxel Injection is contraindicated in patients with: • neutrophil counts of

Warnings

5. WARNINGS AND PRECAUTIONS • Second primary malignancies: In patients treated with docetaxel-containing regimens, monitor for delayed AML, MDS, NHL, and renal cancer. ( 5.7 ) • Cutaneous reactions: Reactions including erythema of the extremities with edema followed by desquamation may occur. Severe cutaneous adverse reactions have been reported. Severe skin toxicity may require dose adjustment or permanent treatment discontinuation. ( 5.8 ) • Neurologic reactions: Reactions including paresthesia, dysesthesia, and pain may occur. Severe neurosensory symptoms require dose adjustment or discontinuation if persistent. …

Pregnancy & breastfeeding

8.1 Pregnancy Risk Summary Based on findings in animal reproduction studies and its mechanism of action, Docetaxel Injection can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . Available data from case reports in the literature and pharmacovigilance with docetaxel use in pregnant women are not sufficient to inform the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fet …

General information only, not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Taxenov Injection 20 mg/mL

Add the expiry date on your pack for a full Trust Score.

3 free checks left today Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Taxenov Injection 20 mg/mL

What is in Taxenov Injection 20 mg/mL?

Taxenov Injection 20 mg/mL contains Docetaxel (Docetaxel Trihydrate) (80 mg/4 mL), as concentrate for solution for infusion, according to its NAFDAC registration record.

Is Taxenov Injection 20 mg/mL registered with NAFDAC?

Yes. Taxenov Injection 20 mg/mL is listed on the NAFDAC register under registration number A4-101586, and its registration is active as of 28 October 2026.

Has Taxenov Injection 20 mg/mL been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Taxenov Injection 20 mg/mL in our automatically synced alert list.

How can I check that my pack of Taxenov Injection 20 mg/mL is genuine?

Run a free authenticity scan with the NAFDAC number A4-101586, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Taxenov Injection 20 mg/mL used for?

1. INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum ther (Summarised from the official U.S. FDA label for docetaxel (docetaxel trihydrate). Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Taxenov Injection 20 mg/mL? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.